Evidence map›Paper›PMID 40799399›Full record

ArticleiScience2025

TGF-β and IL-12 conversely orchestrate the formation of CD103

Stéphanie Corgnac, Isabelle Damei, Chiara Gentile, Aziza Caidi, Séverine Badel, Mélanie Phayanouvong, Fathia Mami-Chouaib

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stéphanie CorgnacINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.
Isabelle DameiINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.
Chiara GentileINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.
Aziza CaidiINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.
Séverine BadelINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.
Mélanie PhayanouvongINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.
Fathia Mami-ChouaibINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accumulation of CD103

Indexed as

CancerImmune responseMicroenvironment

Identifiers

PMID40799399
PMCPMC12341530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.